Notify me when Adjuvant Global Health Technology Fund, L.P. files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | Common Stock, $0.00001 par value per share | 7.9% | $3,061,815 | 2,373,500 | Adjuvant Capital GP, L.P. | 31 Dec 2024 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|